Please Note:This BioForum is a stand-alone event, as well as being Day 1 of the Masterclass program. Registered Masterclass participants are not required to register separately to attend.
Biotech R&D prioritisation has been a major focal point during the pandemic, with collaboration between companies and capitalisation on R&D tax credits both crucial elements for market success.
Over the past two years, global biotech and pharmaceutical sectors saw record levels of investment. With both the number and proceeds of IPOs reaching all-time highs, it was evident that the market was backing the industry.
But as we move away from the peak of the pandemic and the frothiness of the market subsides, has the bubble now burst with a biotech sell-off?
What does the IPO landscape look like now for early-stage companies in 2022 and beyond? Will they be struggling to secure investment in the current economic environment? And have pre-IPO capital raising strategies now fundamentally changed as a result?
Join us on Tuesday 24 May to hear from industry experts who will explore these questions and more.
Dr Graeme Wald Managing Director, Drawbridge Pharmaceuticals Ltd
Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA.
He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research.
He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in then sector and was Chairman of the Risk & Audit Committee of Nexvet while a director of the company through to its NASDAQ listing. He was founding Chairman of Prota Therapeutics and acting CEO.
Michael Kenny Partner, Gadens
Michael is a Partner in the Corporate Team at Gadens specialising in capital markets and mergers & acquisitions. He has over 12 years’ experience advising on a range of equity capital markets transactions and related matters, including pre-IPO capital raising, initial public offerings, secondary raisings, employee share ownership plans and securities law matters.
Michael consistently demonstrates deep knowledge and understanding of the complex regulatory landscape which enables him to deliver commercial outcomes in an efficient and expedient manner for his clients. Organisations looking to raise capital and investment banks underwriting capital transactions trust Michael's expertise in navigating commercial concerns and achieving transaction objectives.
Michael advises both domestic and international clients in number of industries, including health, IT consulting and software products, financial services, funds management, retail energy, property, manufacturing and retail.
Associate Professor Robyn Lindley, Director, Chief Scientific Officer, GMDx Genomics
Associate Professor Robyn A. Lindley is a Founder, Director and the Chief Scientific Officer of GMDx Genomics, Melbourne. She is also an Honorary Senior Fellow in the Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne.
Although her first degrees are in physics and informatics, Robyn is an immunogeneticist who has been publishing on the relationships between inflammation, disease progression and somatic mutation signatures. Robyn is the sole discoverer of the specific codon-contexted targeted somatic mutation (TSM) signatures of nucleotide-specific deaminase enzymes that are now heavily implicated in many cancers. She was also the first to show that some of these changes can be used to predict cancer progression. She was the recipient of the RD Wright medal in 2016, University of Melbourne, for 'marching to the beat of her own drum'. Robyn's foundation research is now being used to develop new genetic tests to predict patient response to immuno-oncology drugs and cancer progression for use in the North American market.